Last updated: September 7, 2026
Ceftaroline fosamil is a hospital-focused cephalosporin antibiotic marketed in the United States as Teflaro and in Europe and other markets as Zinforo. The product targets acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Its commercial trajectory has been constrained by intravenous-only administration, antimicrobial-stewardship controls, competition from established generic antibiotics, and the absence of a large outpatient market.
The product originated with Forest Laboratories, later passed through Actavis and Allergan, and is now part of AbbVie’s legacy portfolio. AbbVie does not separately disclose current ceftaroline revenue, preventing a reliable standalone estimate of recent sales. Ceftaroline remains commercially relevant as a hospital reserve antibiotic, but it is no longer a major growth asset for its owners.
What is ceftaroline fosamil and how is it used?
Ceftaroline fosamil is an intravenous prodrug converted in vivo to ceftaroline, a broad-spectrum cephalosporin with activity against MRSA and susceptible Gram-negative organisms. The FDA approved Teflaro in October 2010 for:
- Acute bacterial skin and skin-structure infections
- Community-acquired bacterial pneumonia
The drug is administered intravenously, generally as a 600 mg dose every 12 hours in adults with normal renal function. Dose adjustment is required for renal impairment. The FDA label includes pediatric use for patients two months of age and older, subject to age- and weight-based dosing considerations. The label does not establish ceftaroline as a treatment for all serious MRSA or resistant Gram-negative infections, and off-label use is controlled by institutional protocols. (FDA, 2024a)
Ceftaroline’s principal clinical differentiator is beta-lactam activity against MRSA through binding to altered penicillin-binding protein 2a. That characteristic separates it from many conventional cephalosporins. Its commercial limitations include IV administration, twice-daily dosing in many patients, and restricted use in hospitals to preserve activity against resistant pathogens.
What is the FDA regulatory status of Teflaro?
Teflaro was approved under New Drug Application 200327. The original approval was based on randomized clinical studies in complicated skin infections and community-acquired pneumonia. FDA labeling later expanded to include pediatric patients.
| Regulatory item |
Status |
| Active ingredient |
Ceftaroline fosamil |
| Brand |
Teflaro |
| U.S. applicant at launch |
Forest Laboratories |
| Current corporate ownership lineage |
Forest, Actavis, Allergan, AbbVie |
| FDA approval |
October 2010 |
| Main indications |
ABSSSI and CABP |
| Route |
Intravenous |
| Pediatric labeling |
Expanded after initial approval |
| Controlled-substance status |
Not a controlled substance |
| Biosimilar pathway |
Not applicable |
Ceftaroline is a small-molecule antibacterial drug, not a biologic. Biosimilar regulation therefore does not apply. Competitive entry occurs through abbreviated new drug applications, subject to pharmaceutical equivalence, bioequivalence where applicable, manufacturing requirements, and any remaining listed-patent protections.
When does ceftaroline fosamil lose exclusivity?
Ceftaroline’s principal U.S. regulatory exclusivity has expired. Market access is now primarily governed by patent status, generic approvals, contracting economics, and hospital formulary decisions.
The initial five-year new chemical entity exclusivity associated with the 2010 approval expired in 2015. Pediatric exclusivity could extend certain regulatory protections by six months after the completion of qualifying pediatric studies, but it does not recreate broad market exclusivity after the underlying period ends.
The Orange Book historically listed patents associated with ceftaroline and its prodrug. Public patent records identify protection covering the cephalosporin compound, ceftaroline fosamil, and related pharmaceutical compositions. The relevant patent families included U.S. Patent Nos. 6,417,175 and 7,348,327, among others. The oldest core composition protection expired around 2020, while later formulation or composition claims extended into the mid-2020s. Exact enforceability depends on the specific patent claims, terminal disclaimers, pediatric extensions, and whether a particular generic product is covered.
| Exclusivity layer |
Approximate status |
| FDA new chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Historical six-month extension tied to qualifying studies |
| Early core composition patents |
Expired or reached expiry around 2020 |
| Later composition or formulation patents |
Potential protection into the mid-2020s |
| Biologic exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not a principal protection for the approved indications |
The practical commercial question is whether an approved generic can launch without infringing any surviving Orange Book patent. Patent expiry alone does not guarantee immediate generic competition. A generic applicant may file a Paragraph IV certification, wait for patent litigation to resolve, negotiate a settlement, or launch at risk.
What is the Orange Book status of Teflaro?
The Orange Book is the central U.S. source for listed patents, exclusivity, and approved therapeutic-equivalence information. Teflaro’s listing historically included patents related to the active compound and pharmaceutical composition.
The commercial importance of the Orange Book listing has declined as the product has moved beyond its original branded-growth period. Any surviving listed patent can still affect a generic launch, but the impact depends on:
- Whether the patent claims cover the proposed generic product.
- Whether the patent remains enforceable.
- Whether the generic applicant files Paragraph IV or another certification.
- Whether the patent holder sues within the statutory period.
- Whether a court grants a preliminary injunction or final judgment.
- Whether the parties sign a launch-date settlement.
A current transaction or litigation analysis should use the live Orange Book entry for NDA 200327 and current FDA ANDA records. Historical patent expiry dates alone are insufficient to determine present launch risk.
Which companies are challenging or competing with Teflaro?
Ceftaroline competes in a crowded hospital-antibiotic market. The most important alternatives depend on the infection, susceptibility profile, renal function, local resistance patterns, and hospital formulary policy.
Direct and near-direct competitors
| Drug |
Company or ownership |
Key competitive position |
| Vancomycin |
Multiple generic manufacturers |
Standard IV MRSA therapy; low acquisition cost |
| Daptomycin |
Generic and branded legacy products |
MRSA bacteremia and skin-infection alternative |
| Linezolid |
Generic manufacturers |
Oral and IV option; strong step-down utility |
| Ceftobiprole |
Basilea and regional partners |
Broad-spectrum cephalosporin with MRSA activity in approved markets |
| Dalbavancin |
AbbVie legacy portfolio and other rights holders |
Long-acting IV therapy for selected skin infections |
| Oritavancin |
Melinta and partners |
Single-dose or long-acting option for selected ABSSSI cases |
| Tedizolid |
Melinta and generic or regional competitors |
Oxazolidinone option for skin infections |
| Ceftazidime-avibactam |
Pfizer |
Resistant Gram-negative focus, with different primary use |
| Meropenem and other carbapenems |
Multiple generic manufacturers |
Broad-spectrum hospital antibiotics |
Vancomycin remains the key economic benchmark because generic supply is extensive and hospital protocols are well established. Linezolid has an important advantage in patients who can transition to oral therapy. Dalbavancin and oritavancin compete where reduced dosing frequency can avoid hospitalization or facilitate outpatient treatment.
Ceftaroline is strongest when clinicians want a beta-lactam with MRSA coverage and the patient requires inpatient IV therapy. It is weaker in price-sensitive formularies and cases where oral therapy or once-only dosing is practical.
What market dynamics affect ceftaroline fosamil sales?
Hospital-only demand
Ceftaroline’s IV formulation limits prescribing to hospitals, infusion centers, and selected outpatient parenteral antibiotic programs. This structure reduces volume compared with oral antibiotics and makes sales dependent on hospital formularies, group purchasing organizations, and infectious-disease specialists.
Antimicrobial stewardship
Hospitals commonly reserve ceftaroline for situations involving MRSA, intolerance or failure of first-line therapy, mixed infections, or specific susceptibility patterns. Stewardship programs reduce routine use but preserve demand in higher-acuity cases.
Generic competition
Generic vancomycin, linezolid, daptomycin, and other alternatives exert constant price pressure. A generic ceftaroline product would likely reduce branded pricing and could shift hospital purchasing toward lowest-cost therapeutically acceptable suppliers.
Resistance and clinical differentiation
Ceftaroline retains value because it combines beta-lactam pharmacology with MRSA activity. Its value is greatest where clinicians prefer a beta-lactam over vancomycin or where other agents are unsuitable. The drug does not eliminate the need for susceptibility testing or stewardship controls.
Contracting and supply reliability
Hospital antibiotic purchases are influenced by contract price, shortage history, manufacturing reliability, and wholesaler availability. A smaller supplier can gain share if it offers dependable supply and competitive pricing, even without clinical differentiation.
What has been the financial trajectory of ceftaroline fosamil?
Ceftaroline generated commercial revenue during Forest Laboratories’ expansion of its branded hospital portfolio. Forest disclosed Teflaro revenue in its annual reports, but the product was materially smaller than the company’s leading outpatient medicines. After Actavis acquired Forest in 2014, Teflaro became part of a broad specialty and hospital portfolio. Allergan inherited the product after Actavis’s subsequent transactions, and AbbVie acquired Allergan in 2020.
The financial trajectory can be divided into four periods:
| Period |
Financial and commercial profile |
| 2010-2013 |
Launch and formulary-building phase; investment focused on hospital adoption |
| 2014-2017 |
Broader commercial ownership under Actavis and Allergan; revenue remained a niche hospital contribution |
| 2018-2020 |
Mature branded product with limited growth and increasing generic-price pressure across the antibiotic class |
| 2021 onward |
Legacy portfolio product; AbbVie does not separately report current ceftaroline revenue |
The lack of current product-level disclosure means analysts should not treat AbbVie’s reported Immunology, Oncology, Neuroscience, or other segment revenue as a proxy for Teflaro sales. The product is too small to be separately identified in AbbVie’s principal financial reporting.
Revenue exposure is therefore best assessed through market share, hospital contracting, patent timing, and generic-entry probability rather than through corporate segment growth. The principal downside event is a sustained generic launch. The principal upside case is limited, consisting of stable hospital use, supply disruptions affecting competitors, or clinical adoption in selected resistant infections.
What patent litigation affects ceftaroline fosamil?
No major, widely reported U.S. patent dispute has defined the product’s current commercial position in the manner seen with high-revenue oncology or immunology drugs. The key litigation risk remains generic-entry litigation under the Hatch-Waxman framework.
A Paragraph IV challenge would typically allege that the listed patent is invalid, unenforceable, or not infringed. If the brand holder files suit within the statutory period, FDA approval of the ANDA can be stayed for up to 30 months, subject to statutory exceptions and court developments. A settlement could establish a future generic launch date, but any such agreement would require review under applicable antitrust and pharmaceutical-settlement standards.
Publicly available corporate filings do not identify ceftaroline as a material current litigation exposure for AbbVie. That reduces the probability of a high-value settlement-driven delay, but it does not eliminate product-specific patent risk.
What formulations are protected by ceftaroline patents?
The relevant intellectual-property estate has centered on:
- Ceftaroline and related cephalosporin chemical structures
- Ceftaroline fosamil as a prodrug
- Pharmaceutical compositions
- Injectable formulations
- Manufacturing and preparation processes
- Salt, solvate, or stability-related claims where applicable
The commercial significance of formulation and process patents is lower than that of the core composition patent once multiple suppliers can manufacture an equivalent injectable product. Process patents can still delay or increase the cost of generic entry if the most efficient manufacturing route is claimed.
Manufacturing barriers are moderate rather than prohibitive. Ceftaroline is an injectable beta-lactam requiring sterile production, validated aseptic processing, stability control, and reliable supply of active pharmaceutical ingredient. These requirements are more demanding than those for an ordinary oral tablet but do not create biologic-level manufacturing barriers.
How strong is the ceftaroline fosamil patent estate?
The patent estate is commercially weak relative to newer branded drugs because the principal regulatory exclusivity has expired and the core product has reached late lifecycle status. Its remaining strength depends on whether later patents cover commercially important aspects of the injectable product and whether generic applicants can design around them.
| Factor |
Assessment |
| Core composition protection |
Largely exhausted or near exhaustion |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Potentially relevant through the mid-2020s, depending on claim scope |
| Manufacturing protection |
Potential barrier for specific processes |
| Brand switching costs |
Low to moderate |
| Hospital clinical differentiation |
Moderate in selected MRSA cases |
| Generic-entry risk |
High once surviving patents no longer block approval |
| Long-term revenue durability |
Low |
How does ceftaroline compare with ceftobiprole?
Ceftaroline and ceftobiprole are both advanced cephalosporins with MRSA activity, but their commercial positions differ.
| Attribute |
Ceftaroline fosamil |
Ceftobiprole medocaril |
| Approved U.S. uses |
ABSSSI and CABP |
Broader U.S. indications after later approval, including bacteremia and certain pneumonia uses |
| Administration |
IV |
IV |
| MRSA activity |
Yes |
Yes |
| Ownership |
AbbVie legacy product |
Basilea and regional partners |
| Lifecycle position |
Mature and exposed to generic pressure |
Newer growth and exclusivity profile |
| Commercial risk |
Low growth, generic substitution |
Regulatory execution, pricing, and adoption risk |
Ceftobiprole has a stronger opportunity to capture growth where its labeling is broader, while ceftaroline has greater historical awareness and an established hospital presence. The two products can compete directly in MRSA treatment but are also differentiated by labeling, local formularies, and physician familiarity.
What generic launch scenarios exist for ceftaroline?
Three scenarios are commercially relevant:
- Generic launch after patent clearance. Hospital buyers switch rapidly where therapeutic substitution is permitted and supply is reliable.
- Limited generic penetration. The brand retains contracts or clinical preference, but price declines and market share erodes gradually.
- Delayed entry through patent litigation or settlement. The brand retains a temporary protected position, but the value of the delay is limited because the product is already mature.
The most likely long-term outcome is declining branded revenue with a transition to a price-driven hospital market. A generic entrant does not need to displace all use to materially affect economics. Even modest formulary conversion can reduce net sales because hospital purchasing is concentrated among large accounts and group purchasing organizations.
What geographic markets does ceftaroline fosamil cover?
Teflaro is the principal U.S. brand. Zinforo has been commercialized in markets outside the United States, including Europe, under regional regulatory approvals and commercial arrangements. Geographic performance has varied because antibiotic reimbursement, hospital procurement, resistance patterns, and regulatory labels differ by country.
The strongest markets are those with:
- High MRSA treatment demand
- Hospital reimbursement for newer IV antibiotics
- Infectious-disease specialist involvement
- Procurement systems that reward clinical differentiation
- Limited access to newer long-acting alternatives
International sales have not been separately disclosed at a level that supports a reliable global revenue estimate. The product’s global value is constrained by its hospital-only route and competition from generic agents.
What is the investment outlook for ceftaroline fosamil?
Ceftaroline is a mature specialty antibiotic rather than a growth asset. Its investment profile is characterized by:
- Limited current revenue transparency
- Expired regulatory exclusivity
- High sensitivity to generic entry
- Modest clinical differentiation
- Low probability of material sales expansion
- Potential value from stable hospital demand and supply reliability
For a buyer or licensee, the asset may have value in a hospital-antibiotic portfolio with existing sales infrastructure. Its standalone strategic value is lower because marketing costs, contracting requirements, and manufacturing complexity can absorb a meaningful portion of net sales.
For AbbVie, ceftaroline is unlikely to affect consolidated financial guidance materially. For a generic manufacturer, the opportunity depends on patent clearance, sterile manufacturing capacity, and the ability to secure hospital contracts. For a specialty-pharma acquirer, the product offers defensive hospital revenue rather than a high-growth platform.
Key Takeaways
- Ceftaroline fosamil is an IV cephalosporin approved for ABSSSI and CABP, with important MRSA activity.
- Teflaro is the U.S. brand; Zinforo is the principal international brand.
- FDA new chemical entity exclusivity has expired.
- Core patent protection has largely expired, while later formulation or composition protections may have extended into the mid-2020s.
- The product is not subject to biosimilar competition because it is a small molecule.
- Hospital stewardship, IV administration, and generic alternatives limit volume growth.
- AbbVie does not separately disclose current ceftaroline revenue.
- Generic entry is the main long-term commercial risk.
- Ceftaroline’s strongest value is as a mature hospital antibiotic with established MRSA utility, not as a growth product.
FAQs
Is ceftaroline fosamil still commercially available?
Yes. Ceftaroline fosamil remains available as the branded product Teflaro in the United States and as Zinforo or equivalent products in certain international markets, subject to local commercialization and supply arrangements.
Is ceftaroline fosamil generic?
Ceftaroline fosamil is the active pharmaceutical ingredient in Teflaro and related products. Whether an approved generic is commercially available depends on the jurisdiction, current FDA ANDA approvals, patent certifications, and supplier launch decisions.
Does ceftaroline treat MRSA bacteremia?
Ceftaroline has activity against MRSA and is used in some cases of MRSA bacteremia, often off label or in salvage-treatment settings. The FDA-approved Teflaro indications are ABSSSI and CABP, not a broad MRSA bacteremia indication.
What is the main commercial advantage of ceftaroline over vancomycin?
Ceftaroline provides MRSA coverage through a beta-lactam mechanism. Clinicians may prefer it in selected patients who need a beta-lactam alternative to vancomycin, but vancomycin remains less expensive and widely established.
Can ceftaroline fosamil become an oral antibiotic?
The marketed product is intravenous. A commercially important oral formulation would require separate development, formulation work, clinical support, and regulatory approval. No approved oral ceftaroline product is part of the established Teflaro label.
References
-
AbbVie Inc. (2024). 2023 annual report. AbbVie.
-
European Medicines Agency. (2024). Zinforo: EPAR product information. European Medicines Agency.
-
Forest Laboratories, Inc. (2014). 2013 annual report. Forest Laboratories.
-
U.S. Food and Drug Administration. (2010). FDA approves Teflaro to treat bacterial skin infections and community-acquired bacterial pneumonia. FDA.
-
U.S. Food and Drug Administration. (2024a). Teflaro (ceftaroline fosamil) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,417,175: Cephalosporin compounds. USPTO.
-
U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,348,327: Cephalosporin compounds and pharmaceutical compositions. USPTO.
